国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產品 » 穩定細胞系 » Human Recombinant Corticotropin Releasing Factor Receptor CRF1 Stable Cell Line
CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.

CHO-K1/CRF1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
M00343
詢價

聯系我們
Product Description Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response
    Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級的網站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 赤城县| 甘泉县| 安远县| 绥德县| 赣榆县| 桦川县| 招远市| 日土县| 鄂温| 交口县| 新野县| 镇宁| 呼图壁县| 饶河县| 延庆县| 阿鲁科尔沁旗| 青川县| 广元市| 湟中县| 齐齐哈尔市| 太谷县| 海晏县| 西丰县| 体育| 晴隆县| 聂荣县| 辽源市| 小金县| 阳东县| 蒲城县| 阳山县| 雅安市| 辽宁省| 深水埗区| 柘城县| 丹寨县| 阳山县| 盖州市| 德令哈市| 德钦县| 罗甸县|